CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
Castells-Roca, Laia ![ORCID Identifier](/img/uab/orcid.ico)
(Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Tejero, Eudald (Institut d'Investigació Biomèdica Sant Pau)
Rodríguez-Santiago, Benjamín ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Surrallés i Calonge, Jordi ![ORCID Identifier](/img/uab/orcid.ico)
(Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Date: |
2021 |
Abstract: |
Cancer is a complex disease resulting from the accumulation of genetic dysfunctions. Tumor heterogeneity causes the molecular variety that divergently controls responses to chemotherapy, leading to the recurrent problem of cancer reappearance. For many decades, efforts have focused on identifying essential tumoral genes and cancer driver mutations. More recently, prompted by the clinical success of the synthetic lethality (SL)-based therapy of the PARP inhibitors in homologous recombinant deficient tumors, scientists have centered their novel research on SL interactions (SLI). The state of the art to find new genetic interactions are currently large-scale forward genetic CRISPR screens. CRISPR technology has rapidly evolved to be a common tool in the vast majority of laboratories, as tools to implement CRISPR screen protocols are available to all researchers. Taking advantage of SLI, combinatorial therapies have become the ultimate model to treat cancer with lower toxicity, and therefore better efficiency. This review explores the CRISPR screen methodology, integrates the up-to-date published findings on CRISPR screens in the cancer field and proposes future directions to uncover cancer regulation and individual responses to chemotherapy. |
Grants: |
Ministerio de Ciencia e Innovación CB06-07-0023 Ministerio de Ciencia e Innovación RTI2018-098419-B-I00
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Language: |
Anglès |
Document: |
Article de revisió ; Article ; Versió publicada |
Subject: |
CRISPR screen ;
Synthetic lethality ;
Combinatorial therapy ;
Cancer therapeutic resistance |
Published in: |
Cancers, Vol. 13 Núm. 7 (2021) , p. 1591, ISSN 2072-6694 |
DOI: 10.3390/cancers13071591
PMID: 33808217
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Published articles
Record created 2021-04-09, last modified 2024-02-27